Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

Gastroenterology
N ChibaR H Hunt

Abstract

Esophagitis healing proportions are often incorrectly called the healing rate. The aim of this study was to compare different drug classes by expressing the speed of healing and symptom relief through a new approach. A fully recursive literature search to July 1996 identified 43 articles on gastroesophageal reflux disease (GERD) (7635 patients) meeting strict inclusion criteria: single- or double-blind randomized studies in adults with endoscopically proven erosive or ulcerative esophagitis. For each drug class, linear regression analysis estimated the average percentage of patients who were healed and heartburn free per week. Mean overall healing proportion irrespective of drug dose or treatment duration (< or =12 weeks) was highest with proton pump inhibitors (PPIs; 83.6% +/- 11.4%) vs. H2-receptor antagonists (H2RAs; 51.9% +/- 17.1%), sucralfate (39.2% +/- 22.4%), or placebo (28.2% +/- 15.6%). Correcting for patients without baseline heartburn, the mean heartburn-free proportion was highest with PPIs (77.4% +/- 10.4%) vs. H2RAs (47.6% +/- 15.5%). PPIs showed a significantly faster healing rate (11.7%/wk) vs. H2RAs (5.9%/wk) and placebo (2.9%/wk). PPIs provided faster, more complete heartburn relief (11.5%/wk) vs. H2RAs (6.4%...Continue Reading

Citations

Oct 7, 2010·Current Gastroenterology Reports·George SachsRichard Hunt
Sep 3, 2003·Journal of General Internal Medicine·Bart van PinxterenPeter A L Bonis
Mar 15, 2002·The New England Journal of Medicine·Stuart Jon Spechler
Oct 17, 2008·The New England Journal of Medicine·Peter J Kahrilas
May 2, 2003·Annals of Surgery·William O RichardsKenneth W Sharp
Jun 20, 1998·BMJ : British Medical Journal·J P GalmicheC Scarpignato
Jul 21, 2000·The Western Journal of Medicine·D A Katzka
Jan 22, 2000·Gut·G Triadafilopoulos
Apr 16, 2002·Gut·J Dent
May 16, 2006·Digestive Diseases·Carmelo ScarpignatoFrancesco Di Mario
Dec 27, 2007·PloS One·Beverley J SheaJeremy M Grimshaw
Mar 25, 2008·Therapeutics and Clinical Risk Management·Theo Scholten
Apr 8, 2011·World Journal of Gastroenterology : WJG·Takao TsuzukiKazuhide Yamamoto
Sep 26, 2001·Postgraduate Medicine·A Kaynard, K Flora
Aug 4, 2010·Expert Review of Gastroenterology & Hepatology·Fabio Pace, Marina Pace
Nov 6, 2012·Expert Review of Clinical Pharmacology·Frank Zerbib, Mireille Simon
Aug 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·David A Johnson
May 1, 2009·Expert Review of Clinical Pharmacology·Alex Mejia, Walter K Kraft
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Dawn D Ferguson, Kenneth R DeVault
May 11, 2005·Expert Opinion on Investigational Drugs·Michael E Parsons, David J Keeling
Oct 5, 2001·Expert Opinion on Pharmacotherapy·M StorrH D Allescher
Aug 5, 2009·Expert Opinion on Emerging Drugs·G E Boeckxstaens
Apr 29, 2015·Expert Opinion on Drug Safety·Marc Bardou, Kyle J Fortinsky
Feb 16, 2005·Expert Opinion on Pharmacotherapy·Frank Serge Lehmann, Christoph Beglinger
Mar 4, 2011·Annals of Medicine·Tiberiu HershcoviciRonnie Fass
Sep 2, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Henning BlumeBarbara S Schug
Apr 26, 2015·The Kaohsiung Journal of Medical Sciences·Wen-Hung HsuChao-Hung Kuo
Feb 8, 2014·Gastroenterology Clinics of North America·Marcelo F Vela
Nov 26, 2013·Clinics in Geriatric Medicine·Amir SoumekhPhilip O Katz
Jan 22, 2013·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·An Jiang WangXuan Zhu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.